• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人表皮生长因子受体2阳性神经内分泌乳腺癌：病例报告及文献综述

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.

作者信息

Gevorgyan Arpine, Bregni Giacomo, Galli Giulia, Zanardi Elisa, de Braud Filippo, Di Cosimo Serena

机构信息

Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

Medical Oncology Unit 1, IRCCS AOU San Martino-IST, Genoa, Italy.

出版信息

Breast Care (Basel). 2016 Dec;11(6):424-426. doi: 10.1159/000453572. Epub 2016 Dec 9.

DOI:10.1159/000453572
PMID:28228710
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5290429/
Abstract

BACKGROUND

Neuroendocrine carcinoma is an uncommon histology for breast cancer.

CASE REPORT

Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.

摘要

背景

神经内分泌癌是乳腺癌中一种不常见的组织学类型。

病例报告

我们的患者于1984年因神经内分泌癌接受了右象限切除术，并在30年后出现骨转移。经过全面的病理和免疫组化分析，确诊了病情，并观察到HER2扩增。在此，我们讨论晚期神经内分泌乳腺癌中HER2靶向治疗的管理、原理及结果。

相似文献

1
HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.人表皮生长因子受体2阳性神经内分泌乳腺癌：病例报告及文献综述
Breast Care (Basel). 2016 Dec;11(6):424-426. doi: 10.1159/000453572. Epub 2016 Dec 9.
2
[Asynchronous Bilateral Neuroendocrine Breast Carcinoma - A Case Report].[非同步双侧神经内分泌乳腺癌——一例报告]
Gan To Kagaku Ryoho. 2018 Apr;45(4):682-684.
3
Case report of primary small cell neuroendocrine breast cancer.原发性小细胞神经内分泌乳腺癌病例报告
Clujul Med. 2013;86(2):156-9. Epub 2013 May 9.
4
Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.曲妥珠单抗在治疗 HER2 阳性转移性乳腺癌中的应用。
Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24.
5
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.HER2扩增水平并非基于曲妥珠单抗辅助治疗的HER2阳性乳腺癌的预后因素：一项系统评价和荟萃分析。
Oncotarget. 2016 Sep 27;7(39):63571-63582. doi: 10.18632/oncotarget.11541.
6
Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.免疫组化HER2评分2+且荧光原位杂交检测显示HER2基因扩增的转移性乳腺癌对曲妥珠单抗单药治疗反应良好：一例报告
Breast Cancer. 2003;10(2):170-4. doi: 10.1007/BF02967645.
7
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
8
Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with gene amplification: A case report.曲妥珠单抗联合化疗对基因扩增的复发性膀胱尿路上皮癌的完全缓解：一例报告
World J Clin Cases. 2020 Feb 6;8(3):594-599. doi: 10.12998/wjcc.v8.i3.594.
9
Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.MEL-18 扩增在乳腺癌抗 HER2 治疗中的作用。
J Natl Cancer Inst. 2019 Jun 1;111(6):609-619. doi: 10.1093/jnci/djy151.
10
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.

引用本文的文献

1
Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.病例报告：乳腺神经内分泌癌——文献综述及6例病例展示
Front Med (Lausanne). 2025 Aug 20;12:1551309. doi: 10.3389/fmed.2025.1551309. eCollection 2025.
2
Neuroendocrine neoplasms of the breast: a review of literature.乳腺神经内分泌肿瘤：文献回顾。
Virchows Arch. 2024 Aug;485(2):197-212. doi: 10.1007/s00428-024-03856-y. Epub 2024 Jul 9.
3
HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: A case report and review of literature.具有印戒特征的HER-2阳性原发性乳腺神经内分泌肿瘤：一例报告并文献复习
Front Oncol. 2022 Dec 12;12:1029007. doi: 10.3389/fonc.2022.1029007. eCollection 2022.
4
Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives.乳腺原发性神经内分泌肿瘤：当前认识与未来展望
Front Oncol. 2022 May 25;12:848485. doi: 10.3389/fonc.2022.848485. eCollection 2022.
5
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.乳腺神经内分泌肿瘤：世界卫生组织最新分类及文献综述
Cancers (Basel). 2021 Dec 31;14(1):196. doi: 10.3390/cancers14010196.
6
Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues.乳腺原发性神经内分泌肿瘤：仍存在的问题。
Front Endocrinol (Lausanne). 2021 Jan 26;11:610230. doi: 10.3389/fendo.2020.610230. eCollection 2020.
7
Rare Human Epidermal Growth Factor Receptor 2 (HER-2)-Positive Neuroendocrine Carcinoma of the Breast: A Case Report with 9-Year Follow-up.罕见的人表皮生长因子受体2（HER-2）阳性乳腺神经内分泌癌：一例9年随访病例报告
Am J Case Rep. 2020 Oct 17;21:e925895. doi: 10.12659/AJCR.925895.
8
Neuroendocrine breast carcinoma: a rare but challenging entity.神经内分泌乳腺癌：一种罕见但极具挑战性的实体。
Med Oncol. 2020 Jul 25;37(8):70. doi: 10.1007/s12032-020-01396-4.
9
Neuroendocrine Cancer of the Breast: A Rare Entity.乳腺神经内分泌癌：一种罕见的实体瘤。
J Clin Med. 2020 May 13;9(5):1452. doi: 10.3390/jcm9051452.
10
Classification of Widely and Rarely Expressed Genes with Recurrent Neural Network.基于递归神经网络的广泛表达和稀有表达基因分类
Comput Struct Biotechnol J. 2018 Dec 14;17:49-60. doi: 10.1016/j.csbj.2018.12.002. eCollection 2019.

本文引用的文献

1
Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database.乳腺浸润性神经内分泌癌：来自监测、流行病学和最终结果（SEER）数据库的一项基于人群的研究。
BMC Cancer. 2014 Mar 4;14:147. doi: 10.1186/1471-2407-14-147.
2
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.乳腺局部晚期神经内分泌癌：病例报告及文献复习。
World J Surg Oncol. 2013 Jun 5;11:128. doi: 10.1186/1477-7819-11-128.
3
Primary neuroendocrine breast cancer, how much do we know so far?原发性神经内分泌乳腺癌，目前我们了解多少？
Med Oncol. 2012 Dec;29(4):2613-8. doi: 10.1007/s12032-012-0222-z. Epub 2012 Apr 1.
4
Expression of the neuroendocrine phenotype in carcinomas of the breast.
Semin Diagn Pathol. 2000 May;17(2):127-37.
5
'Carcinoid' tumours of the breast: the morphological spectrum of argyrophil carcinomas.乳腺“类癌”肿瘤：嗜银细胞癌的形态学谱系
Histopathology. 1982 Sep;6(5):549-69. doi: 10.1111/j.1365-2559.1982.tb02750.x.
6
Chromogranin-reactive endocrine cells in argyrophilic carcinomas ("carcinoids") and normal tissue of the breast.嗜银癌（“类癌”）及乳腺正常组织中的嗜铬粒蛋白反应性内分泌细胞。
Am J Pathol. 1985 Aug;120(2):186-92.